Regenxbio Inc Total Assets
Regenxbio Inc total assets. Based on the latest financial reports, Regenxbio Inc (RGNX) holds total assets worth $386.62 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Regenxbio Inc for the company's overall valuation and market capitalisation.
Total Assets of Regenxbio Inc (2013–2025)
Total assets of Regenxbio Inc from 2013 to 2025. This chart illustrates how Regenxbio Inc's total assets have evolved over time, based on quarterly financial data. See Regenxbio Inc share price for real-time trading data and today's change.
Regenxbio Inc - Asset Composition Analysis
Regenxbio Inc Total Assets Breakdown (December 2025)
Regenxbio Inc total assets breakdown as of December 2025. Regenxbio Inc's total assets of $386.62 Million consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.6% |
| Accounts Receivable | $27.38 Million | 6.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Regenxbio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RGNX working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regenxbio Inc's current assets represent 62.1% of total assets in 2025, a decrease from 87.9% in 2013.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2025, down from 44.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Regenxbio Inc Competitors by Total Assets
Key competitors of Regenxbio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Sinocelltech Group Ltd
SHG:688520
|
China | CN¥3.76 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.47 Billion |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
USA | $667.85 Million |
|
GH Research PLC
NASDAQ:GHRS
|
USA | $372.35 Million |
Regenxbio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.86 | 3.13 | 3.84 |
| Quick Ratio | 2.86 | 3.13 | 3.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $153.54 Million | $254.21 Million | $303.39 Million |
Regenxbio Inc - Advanced Valuation Insights
This section examines the relationship between Regenxbio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.89 |
| Latest Market Cap to Assets Ratio | 1.08 |
| Asset Growth Rate (YoY) | -2.8% |
| Total Assets | $453.03 Million |
| Market Capitalization | $487.18 Million USD |
Valuation Analysis
Above Book Valuation: The market values Regenxbio Inc's assets above their book value (1.08x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Regenxbio Inc's assets decreased by 2.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Regenxbio Inc (2013–2025)
The table below shows the annual total assets of Regenxbio Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $453.03 Million | -2.78% |
| 2024-12-31 | $465.99 Million | -18.81% |
| 2023-12-31 | $573.97 Million | -31.12% |
| 2022-12-31 | $833.27 Million | -25.19% |
| 2021-12-31 | $1.11 Billion | +57.29% |
| 2020-12-31 | $708.16 Million | +42.23% |
| 2019-12-31 | $497.91 Million | -8.44% |
| 2018-12-31 | $543.81 Million | +173.72% |
| 2017-12-31 | $198.68 Million | +15.02% |
| 2016-12-31 | $172.73 Million | -21.97% |
| 2015-12-31 | $221.38 Million | +6241.45% |
| 2014-12-31 | $3.49 Million | +39.08% |
| 2013-12-31 | $2.51 Million | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more